Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis

Drugs

Volumn 78, Issue 9, 2018, Pages 929-940

  Lamb, Yvette N ^a   Deeks, Emma D ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; SARILUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ABNORMAL LABORATORY RESULT; ARTICLE; CARDIOVASCULAR DISEASE; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; HEADACHE; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MALIGNANT NEOPLASM; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; THERAPY EFFECT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; DRUG APPROVAL; EUROPE; JAPAN; METABOLISM; TREATMENT OUTCOME; UNITED STATES;

ADALIMUMAB; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG APPROVAL; EUROPE; HUMANS; JAPAN; METHOTREXATE; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 85048256507     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-018-0929-z     Document Type: Article

References (46)

1. Raimondo MG, Biggioggero M, Crotti C, et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Dev Ther. 2017;11:1593–603.
2. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.
3. Singh JA, Saag KG, Bridges SLJ, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
4. Marchesoni A, Zaccara E, Gorla R, et al. TNF-α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173(1):837–46.
5. Srirangan S, Choy CH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskel Dis. 2010;2(5):247–56.
6. ® (sarilumab) injection, for subcutaneous use. 2017. http://products.sanofi.us/. Accessed 29 May 2018.
7. European Medicines Agency. Kevzara: summary of product characteristics 2017. http://www.ema.europa.eu/. Accessed 29 May 2018.
8. Potocky T, Rafique A, Fairhurst J, et al. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor alpha (il-6rα) [abstract no. ICW-C15-3]. Mod Rheumatol. 2016;26(Suppl):S69–70.
9. European Medicines Agency. Kevzara: CHMP assessment report. 2017. http://www.ema.europa.eu/. Accessed 29 May 2018.
10. Dougados M, Choy EH, Kameda H, et al. IL-6R blockade with sarilumab plus methotrexate results in changes in clinical and laboratory parameters associated with chronic inflammation in patients with moderate-to-severe RA in a phase 3 study [abstract no. 2761]. Arthritis Rheumatol. 2015;67(Suppl 10):3336–8.
11. Gabay C, Msihid J, Daskalakis N, et al. Effect of sarilumab on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors [abstract no. 2615]. Arthritis Rheumatol. 2016;68(Suppl 10):2615.
12. Gabay C, Msihid J, Paccard C, et al. Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 MONARCH study [abstract no. FRI0227]. Ann Rheum Dis. 2017;76(Suppl 2):570.
13. Emery P, Rondon J, Garg A, et al. Safety and tolerability of subcutaneous sarilumab compared to intravenous tocilizumab in patients with RA [abstract no. 971]. Arthritis Rheumatol. 2015;67(Suppl 10):1268–9.
14. Kovalenko P, Paccaly A, Boyapati A, et al. Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA) after single-dose administration [abstract no. 7284 and poster III-58]. In: Annual meeting of the population approach group in Europe. 2017.
15. Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016;18(1):225.
16. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840–7.
17. Xu C, Su Y, Paccaly A, et al. Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis [abstract no. 7283]. In: Annual meeting of the population approach group in Europe. 2017.
18. Lee EB, Daskalakis N, Xu C, et al. Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet. 2017;56(6):607–15.
19. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277–90.
20. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–37.
21. Sanofi. A study assessing the efficacy and safety of sarilumab added to MTX in Japanese patients with moderately to severely active rheumatoid arthritis (SARIL-RA-KAKEHASI) [ClinicalTrials.gov identifier NCT02293902] US National Institutes of Health, ClinicalTrials.gov. 2017. http://www.clinicaltrials.gov/. Accessed 29 May 2018.
22. Sanofi. Long term evaluation of sarilumab in rheumatoid arthritis patients (SARIL-RA-EXTEND) [ClinicalTrials.gov identifier NCT01146652] US National Institutes of Health, ClinicalTrials.gov. 2017. http://clinicaltrials.gov/. Accessed 29 May 2018.
23. Burmester GR, Fiore S, Hu C-C, et al. Efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of a phase 3 monotherapy trial in patients with active rheumatoid arthritis [abstract no. 2482]. Arthritis Rheumatol. 2017;69(Suppl 10):2482.
24. Burmester GR, Lin Y, Mangan EK, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis in the phase 3 MONARCH study, including subpopulations [abstract no. SAT0202]. Ann Rheum Dis. 2017;76(Suppl 2):849.
25. Emery P, van Hoogstraten H, Jayawardena S, et al. Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab [abstract no. 2468]. Arthritis Rheumatol. 2017;69(Suppl 10):2468.
26. Fleischmann R, Hrycaj P, van Hoogstraten H, et al. Sarilumab dose reduction in an open-label extension study in RA patients with inadequate response to TNF inhibitors [abstract no. SAT0212]. Ann Rheum Dis. 2017;76(Suppl 2):853.
27. Fleischmann R, Mangan EK, van Adelsberg J, et al. Onset of action of sarilumab in patients with rheumatoid arthritis in 2 phase 3 studies [abstract no. SAT0180]. Ann Rheum Dis. 2016;75(Suppl 2):733.
28. Genovese M, Fleischmann R, Mangan E, et al. Efficacy and safety of sarilumab in subgroups of patients with rheumatoid arthritis from 2 phase 3 studies [abstract no. 1632]. Arthritis Rheumatol. 2016;68(Suppl 10):1632.
29. Genovese MC, Fay J, Parrino J, et al. Sarilumab dose reduction in an open-label extension study in RA patients [abstract no. 1631]. Arthritis Rheumatol. 2016;68(Suppl 10):1631.
30. Tanaka Y, Sato M, Sumi M, et al. Efficacy of sarilumab, human anti–IL-6 receptor monoclonal antibody in KAKEHASI study, phase 3 trial for Japanese rheumatoid arthritis patients [abstract no. W13-2]. Mod Rheumatol. 2017;27(Suppl):S97.
31. van der Heijde D, van Adelsberg J, van Hoogstraten H, et al. Clinical and radiographic outcomes after 3 years of sarilumab in patients with rheumatoid arthritis [abstract no. 1633]. Arthritis Rheumatol. 2016;68(Suppl 10):1633.
32. ® subcutaneous injection (150 mg and 200 mg) 2017. http://www.pmda.go.jp/. Accessed 29 May 2018.
33. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73(9):1626–34.
34. Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.
35. Strand V, Reaney M, Chen CI, et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. RMD Open. 2017;3(1):e000416.
36. Genovese MC, van Adelsberg J, Fan C, et al. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology (Oxford). 2018. 10.1093/rheumatology/key121.
37. Kameda H, Sato M, Sumi M, et al. Safety of sarilumab, a novel human anti–IL-6 receptor monoclonal antibody: safety outcome at 24 weeks in placebo-controlled double-blind study for Japanese rheumatoid arthritis patients (KAKEHASI study) [abstract no. W13-3]. Mod Rheumatol. 2017;27(Suppl):S97.
38. American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Appendix 5: executive summary. 2015. http://www.rheumatology.org/. Accessed 29 May 2018.
39. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
40. Wright HL, Cross AL, Edwards SW, et al. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford). 2014;53(7):1321–31.
41. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921–6.
42. European Medicines Agency. RoActemra 20 mg/ml concentrate for solution for infusion: summary of product characteristics. 2017. http://www.ema.europa.eu/. Accessed 29 May 2018.
43. June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303–9.
44. Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36:685–95.
45. Fournier M, Chen C-I, Kuznik A, et al. Sarilumab for the treatment of active, moderate-to-severe rheumatoid arthritis (RA): an analysis of cost per effectively treated patient [abstract no. 2457]. Arthritis Rheumatol. 2017;69(Suppl 10):2457.
46. Rischin A, Östör AJK. Update on biosimilars in rheumatology. Immunopharmacology. 2017;25:177–84.